Hemal Mehta speaks to us about the current management options for wet age-related macular degeneration (AMD), including intravitreal injections of anti-VEGF agents and other injection-based therapy, and their treatment burden. He then discusses the new PanOptica Eye Drop, a topical treatment for wet AMD.

Questions:
1. What are the areas of unmet need in the management of Wet age-related macular degeneration (AMD)? (0:08)
2. How could a drop therapy for Wet AMD benefit patients? (1:03)
3. How does the PanOptica drop being studied work? (1:58)
4. How far have the clinical studies of this molecule progressed? (2:54)
5. How can patients find out where the clinical trial is running? (4:08)
6. If the drop has benefit in clinical trials, how long would it be until it is available in eye clinics? (4:53)

Speaker disclosures: Mr Hemal Mehta has received research grants and honoraria from Allergan, Bayer and Novartis.

Filmed at the European Society of Retina Specialists (EURETINA) 2018 Congress, Vienna, Austria, 20–23 September 2018.

свернуть